Late-onset and long-lasting autoimmune neutropenia: an analysis from the Italian Neutropenia Registry.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
24 11 2020
24 11 2020
Historique:
received:
25
06
2020
accepted:
03
09
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Primary autoimmune neutropenia (pAN) is typified by onset in early infancy and a mild/moderate phenotype that resolves within 3 years of diagnosis. In contrast, secondary AN is classically an adult disease associated with malignancy, autoimmunity, immunodeficiency, viral infection, or drugs. This study describes a cohort of 79 children from the Italian Registry who, although resembling pAN, did not fully match the criteria for pAN because neutropenia either appeared after age 5 years (LO-Np) or lasted longer than 3 years (LL-Np). These 2 categories compared with classical pAN showed a far inferior rate of resolution (P < .001), lower severity of neutropenia (P = .03), leukopenia (P < .001), lymphopenia (P < .001) with low B+ (P = .001), increased need of granulocyte colony-stimulating factor (P = .04), and increased frequency of autoimmunity over the disease course (P < .001). A paired comparison between LO-Np and LL-Np suggested that LO-Np had a lower rate of resolution (P < .001) and lower white blood cell (P < .001) and lymphocyte (P < .001) values, higher occurrence of apthae (P = .008), and a stronger association with autoimmune diseases/markers (P = .001) than LL-Np, thus suggesting a more pronounced autoimmune signature for LO-Np. A next-generation sequencing panel applied in a small subgroup of LO-Np and LL-Np patients identified variants related to immune dysregulations. Overall, these findings indicate that there are important differences among pAN LL-Np and LO-Np. Forms rising after 3 years of age, with low tendency to resolution, require tight monitoring and extensive immune investigations aimed to early identify underlying immunologic disease.
Identifiants
pubmed: 33206964
pii: S2473-9529(20)31961-3
doi: 10.1182/bloodadvances.2020002793
pmc: PMC7686904
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5644-5649Informations de copyright
© 2020 by The American Society of Hematology.
Références
J Allergy Clin Immunol. 2007 Nov;120(5):1178-85
pubmed: 17983875
Vox Sang. 2005 Jan;88(1):52-9
pubmed: 15663723
Am J Hematol. 2012 Feb;87(2):238-43
pubmed: 22213173
Blood. 2008 Nov 1;112(9):3594-600
pubmed: 18669893
Blood. 1999 Sep 1;94(5):1797-802
pubmed: 10477706
Vox Sang. 2013 Oct;105(3):259-69
pubmed: 23663230
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1763-1770
pubmed: 30776527
Blood. 2010 Jul 8;116(1):7-15
pubmed: 20332369
Nat Genet. 2005 Aug;37(8):820-8
pubmed: 16007087
Blood. 1998 Jan 1;91(1):181-6
pubmed: 9414283
J Allergy Clin Immunol. 2016 Jan;137(1):223-230
pubmed: 26768763
Expert Rev Clin Immunol. 2019 Nov;15(11):1225-1233
pubmed: 31592698
Am J Hematol. 2017 Sep;92(9):E546-E549
pubmed: 28567966
Arthritis Res Ther. 2005;7(5):208-14
pubmed: 16207350
Blood. 2009 Jun 25;113(26):6511-21
pubmed: 19395674
Am J Hematol. 2015 Dec;90(12):E221-2
pubmed: 26361081